Antimycotics Flashcards
1
Q
What is a fungus?
A
- eukaryotic organism
- cell wall with glucan and chitin
- heterotroph (more then one nutrient is important)
- ergosterol in cell membrane -> mammals have cholesterol
2
Q
Yeasts
A
- candida (albicans, glabrata, krusei, parapsilosis, tropicalis)
- cryptococcus (neoformans, gattii) -> pathogen
3
Q
Molds
A
- diverse
- Aspergillus
- Mucorales
4
Q
Dimorphic fungi
A
- yeast and/or mold
- endemic
- Histoplasma
- Bastomyces
- Coccidioides
- Sporothrix
5
Q
Name the 4 mycoses (classification)
A
- superficial mycoses
- subcutaneous mycoses
- cutaneous mycoses
- systemic mycoses
6
Q
What are the risk groups for systemic fungal infections
A
- stem cells/solid organ transplants
- AIDS patients
- high risk environment
- prolonged antibiotic use
- prolonged neutropenia
7
Q
What are the problems in antimycotic therapy?
A
- fungi are eukaryotic
- cross resistances observed
8
Q
Name the classes of antifungals
A
- Pyrimidines
- Echinocandins
- Polyenes
- Azoles
9
Q
Azoles in more detail
A
- compounds with imidazole or triazole groups
- mode of action: five membered heterocycle binds to heme iron and prevents lanosterol binding to erg11
- contributing to antimycotic effect is toxic sterol (lanosterol is directly combined with erg3 => toxic)
- Fluconazole
10
Q
Polyenes in more detail
A
- obtained from Streptomyces
- amphiphatic
- mode of action: form extramembranous aggregates that „extract“ ergosterol from plasma membrane
- powerful but toxic (extraction of cholesterol) -> last line defense
- Amphotericin B
- Nystatin
11
Q
Echinocandins in more detail
A
- cyclic semisynthetic hexapeptide -> cell wall synthesis disruption
- (1,3)-ß-D-glucan is vital for cell wall integrity
- targets Fks1 ((1,3)-ß-D-glucan synthase) as non-competitive inhibitor
- first line therapy against systemic Candida
- Caspofungin
12
Q
Pyrimidines in more detail
A
- Flucytosine (synthetic fluorinated analogue of cytosine)
- in cytosol flucytosine is rapidly deaminated becoming fluuracil
- 5-fluorouracil causes RNA miscoding
- combination with Amphotericin is gold standard in Cryptococcus therapy
13
Q
Resistance mechanisms
A
- overexpression and/or mutations in erg11
- loss of function mutation in ergosterol synthesis (erg3) -> no toxic sterol
- mutations in Fks1
- efflux pumps against azoles -> overexpression of multi-drug-resistance proteins
- cellular stress response (against azoles) -> overexpression of Hsp90